The Genome Editing market is expected to grow at CAGR of 10.68% to reach USD 8.23 billion by 2025.

Genome editing is defined as the process of modifying the genome within a living cell through the insertion, replacement or deletion of one or more components of DNA. Technology advancements is one of the major driving factor for this industry growth.  There is an increase in the funding by the government organizations for such R&D activities, thus acting as a catalyst to this growth. Advancement in technology such as the development of the CRISPR- Cas9 is a huge milestone in genome editing technology. Recently developed technologies such as transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), clustered regularly interspaced short palindromic repeats (CRISPR) and meganucleases offers huge opportunities for the development of human gene editing therapy.

Global Genome Editing Market Insights provides a specific tool for evaluating the global industry, specifying the growth potentials, supporting tactical and strategic decision-making. This report identifies the latest Genome Editing market information that helps stakeholder to monitor performance and make strategic decisions for development and profitability. This report provides information on the overall industry trends and development patterns, as well as focuses on the markets and upcoming technologies, and on the dynamic nature of the Genome Editing market.

Browse through 120 Tables & 40 Figures spread over 160 Pages and in-depth TOC on “Global Genome Editing Market: Industry Size, Share, Trends, Growth, and Forecast, 2014–2025 at

https://www.analystviewmarketinsights.com/report-highlight-genome-editing-market/

Key Takeaway

• In terms of application, the industry is divided into Animal Genetic Engineering, Cell Line Engineering/Gene Therapy, Plant Genetic Engineering and Other.
• Of these, animal genetic engineering is accounted for the highest revenue share owing to the significant growth of dairy technology. Plant genetic engineering is set to grow with promising growth rate over the study period.
• Gene editing is primarily carried out through ex vivo and in vivo method. Ex Vivo is the largest segment in terms of revenue generation, allows better control over dosages being delivered to the cells.
• Biotechnology & Pharmaceutical Industries, Contract Research Organizations, Academic & Government Research Institutes and others are categorized under end-use. Pharmaceutical and biotechnological companies are spending a significant amount of time on R&D of various diseases and drug delivery and development. Research institutes own about one-third
• Technology wise, the industry is categorized as TALEN/Mega TALs, CRISPR/ Cas9, ZFN and others. Among which, CRISPR- Cas9 captured highest revenue share with over 45% of the segment share. This technology is considered to be the most revolutionary developments in the gene editing sector. 
• This prokaryote-derived genome editing system has transformed the researcher’s ability to detect, manipulate, and annotate specific RNA and DNA sequences in living cells.
• Among the different regions, U.S commanded the largest share of the global market owing to the favourable regulatory scenario for this industry growth.
• On contrary, factors such as favourable goverment initatives, quick adoption of advanced genomic technologies coupled with rising investment by companies support the Asia Pacific regional growth. Countries such as India and China, being an agriculturally driven economies, there is a tremendous opportunity for crops that are genetically more productive and effective.
• Key manufacturers such as CRISPR Therapeutics, Merck KGaA, Intellia Therapeutics, Cibus, Sangamo, Recombinetics, Inc., AstraZeneca plc, Precision Biosciences, Caribou Biosciences, Inc., Editas Medicine Cellectis, Lonza and Horizon Discovery Group are profiled in detail.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY TECHNOLOGY

• CRISPR/ Cas9
• ZFN
• TALEN/Mega TALs
• Others

MARKET, BY APPLICATION

• Cell Line Engineering/Gene Therapy
• Plant Genetic Engineering
• Animal Genetic Engineering
• Others

MARKET, BY DELIVERY MODE

• Ex-vivo
• In-vivo

MARKET, BY END USE

• Biotechnology & Pharmaceutical Industries
• Contract Research Organizations
• Government Research Institutes
• Others

MARKET, BY SERVICE

• In-house
• Contract

MARKET, BY REGION

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Rest of Europe
• Asia Pacific
  • India
  • China
  • Rest of APAC
• Rest of the World
  • Middle East and Africa
  • Latin America